Best Bentonite
Letter data
- Company
- Best Bentonite
- Recipient
- Marshall A. Dunlap | Owner | Best Bentonite | Best Bentonite | 11650 Otis Rd | Guthrie | , | OK | 73044 | United States
- Issue date
- 2018-11-23
- Posted date
- Not available
- FDA office
- United States
- Subject
- Not available
- Product
- Drugs
- CMS ID
- 494502
- Reference number
- 2016-DAL-WL-26
- FEI
- Not available
- Inspection dates
- Not available
Normalized citations
21 CFR: None found
21 U.S.C.: None found
Related FDA links
No related FDA letter link is present in the source index.
Full source text
CLOSEOUT LETTER
Best Bentonite
MARCS-CMS 494502 —
November 23, 2018
More Warning Letters
Warning Letters
About Warning and Close-Out Letters
Delivery Method:
UPS NEXT DAY DELIVERY
Reference #:
2016-DAL-WL-26
Product:
Drugs
Recipient:
Recipient Name
Marshall A. Dunlap
Recipient Title
Owner
Best Bentonite
Best Bentonite
11650 Otis Rd
Guthrie
,
OK
73044
United States
Issuing Office:
United States
Marshall A. Dunlap - Owner
Best Bentonite
11650 Otis Rd
Guthrie, OK 73044
Mr. Dunlap:
The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter 2016-DAL-WL-26 dated June 17, 2016. Based on our evaluation during, it appears that you have addressed the violations contained in this Warning Letter related to your marketing of Best Bentonite. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
LCDR John W. Diehl, M.S.
Director, Compliance Branch
Office of Pharmaceutical Quality Operations,
Division II
Content current as of:
11/30/2018
Regulated Product(s)
Drugs